Resiquimod is under clinical development by Galderma and currently in Phase II for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase II drugs for Cutaneous T-Cell Lymphoma have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Resiquimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Resiquimod overview

Resiquimod is under development for the treatment of cutaneous T-cell lymphoma, mycosis fungoides and metastatic melanoma. It is formulated as a gel and administered by topical route. Resiquimod is an immune response modifier. It acts by targeting toll-like receptors (TLR) 7 and 8. It was also under development for the treatment of nodular basal cell carcinoma (nBCC), warts and multiple actinic keratosis.

Galderma overview

Galderma is a pharmaceutical company that develops and markets medical and consumer skin health products. Galderma provides prescription drugs and aesthetic solutions for the treatment of various skin conditions such as acne, rosacea, psoriasis and steroid-responsive dermatoses, nail mycosis, pigmentary disorders, skin cancer, atopic dermatitis, and sun protection among others. Its major brands include Epiduo, Differin, Oracea, Loceryl, Metvix, Azzalure/Dysport, Mirvaso, Soolantra, Restylane, Cetaphil, and Emervel. The company has its research and development centers and manufacturing sites in Asia-Pacific, the Middle East, Europe, Africa, and North and Latin America. Galderma is headquartered in La Tour-de-Peilz, Vaud, Switzerland.

For a complete picture of Resiquimod’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.